US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Report on operations 2014: Acquisition of FertiliTech and strengthened income

    Fourth quarter · Acquisition of all the shares in Unisense FertiliTech A/S (“FertiliTech”), the market leader in embryo monitoring, time-lapse, for IVF. · Non-cash issue of 1,879,179 shares for part-financing of the acquisition of FertiliTech. · Sales amounted to SEK 137 (124) million, corresponding to an increase of 11 percent in SEK. Sales growth was 4 percent in local currency. Last year’s figure included sales of the transplant product STEEN Solution™ to Xvivo to the tune of SEK 5 million. Adjusted for this, the increase in sales amounted to 8 percent in local currency. ·

    Vitrolife’s share capital and number of shares on November 28, 2014

    As per November 28, 2014, the total number of shares in Vitrolife AB (publ) amounts to 21,710,115, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 22,144,317.30.At the beginning of the month the total number of shares in the company amounted to 19,830,936, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 20,227,554.72. The increase in the number of shares by 1,879,179 during the month of November is due to the non-cash issue of shares with regards to the acquisition of Unisense FertiliTech A/S. November 28, 2014Gothenburg

    Vitrolife AB (publ) completes the acquisition of Unisense FertiliTech A/S and has therefore resolved to carry out a non-cash issue

    In line with the authorization granted by the Annual General Meeting on May 5, 2014, the Board of Vitrolife AB has today resolved to carry out a non-cash issue of1,879,179 shares and thereby complete the acquisition of Unisense FertiliTech A/S (“FertiliTech”).As previously announced, Vitrolife entered into an agreement on November 4, 2014 to acquire all the shares in FertiliTech. In line with the authorization granted by the Annual General Meeting, the Board of Vitrolife has today resolved to carry out a non-cash issue of 1,879,179 shares. These constitute part of the purchase sum for the

    Interim report January-September 2014: Good growth and considerably stronger results

    Third quarter: · Sales growth was 9 percent in local currency. Sales amounted to SEK 125 (109) million, corresponding to an increase of 15 percent in SEK. Last year’s figure included sales of the transplantation product STEEN Solution™ to Xvivo to the tune of SEK 3 million. Adjusted for this, the increase in sales amounted to 12 percent in local currency. · Operating income (EBIT) amounted to SEK 44 (23) million, corresponding to an operating margin of 35 (21) percent. · Net income amounted to SEK 36 (17) million, which gave earnings per share of SEK 1.79 (0.85). January -

    Vitrolife AB (publ) acquires Unisense FertiliTech A/S

    Vitrolife AB has entered into an agreement to acquire all the shares of Unisense FertiliTech A/S (“FertiliTech”), the market leader within the field of embryo monitoring, time-lapse, for IVF.Description of FertiliTechFertiliTech has driven the clinical use of time-lapse imaging for IVF. Their products have been used in more than 200.000 IVF treatments in 47 countries. FertiliTech has its head office in Århus, Danmark. The company was formed in 2003 and has approximately 70 employees. FertiliTech and its subsidiaries had net sales of approximately SEK 94 million in 2013 and reported income

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe